All In Biotech

Drug Trial Radar · NCT06150014

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment-naïve Patients and Treated Patients With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Actual

Start

Dec 7, 2023

Primary completion

Dec 2025

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind Phase Ib/IIa multicenter trial design was used. All eligible subjects received TQA3605 tablets/placebo plus nucleoside (acid) analogues. A total of 88 subjects were required

Conditions

  • Chronic Hepatitis b

Interventions

  • PlaceboDrug

    TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.

  • TQA3605 tabletsDrug

    TQA3605 inhibits viral replication.

  • Entecavir dispersible tabletsDrug

    Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.

  • Tenofovir disoproxil fumarate tabletDrug

    Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.

  • Tenofovir alafenamide fumarate tabletDrug

    Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse events (AEs)Time frame: Up to 48 weeks
  2. Severity of adverse events (AEs)Time frame: Up to 48 weeks
  3. Incidence of serious adverse events (SAEs)Time frame: Up to 48 weeks
  4. Severity of serious adverse events (SAEs)Time frame: Up to 48 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shannxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.